VSTM2L had different prognostic values across cancers: high expression was related to worse prognosis in BLCA, DLBC, GBM, KIRC, LUSC, MESO, OV, STAD, THCA, THYM, UCEC, and UVM but was associated with a good prognosis in KIRP, LGG, and PCPG. This evidence concerns the gene VSTM2L and glioblastoma.